Display options
Cite
Steinmetz NF, Maurer J, Sheng H, et al. Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. Cancers (Basel). 2011;3(3):2870-85doi: 10.3390/cancers3032870.
Steinmetz, N. F., Maurer, J., Sheng, H., Bensussan, A., Maricic, I., Kumar, V., & Braciak, T. A. (2011). Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. Cancers, 3(3), 2870-85. https://doi.org/10.3390/cancers3032870
Steinmetz, Nicole F, et al. "Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133." Cancers vol. 3,3 (2011): 2870-85. doi: https://doi.org/10.3390/cancers3032870
Steinmetz NF, Maurer J, Sheng H, Bensussan A, Maricic I, Kumar V, Braciak TA. Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. Cancers (Basel). 2011 Jul 13;3(3):2870-85. doi: 10.3390/cancers3032870. PMID: 24212937; PMCID: PMC3759176.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2011 Jul 13;3(3):2870-85. doi: 10.3390/cancers3032870.

Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133.

Cancers

Nicole F Steinmetz, Jochen Maurer, Huiming Sheng, Armand Bensussan, Igor Maricic, Vipin Kumar, Todd A Braciak

Affiliations

  1. Case Western Reserve University, Department of Biomedical Engineering, 10900 Euclid Ave, Cleveland, OH 44106, USA. [email protected].

PMID: 24212937 PMCID: PMC3759176 DOI: 10.3390/cancers3032870

Abstract

Vimentin was originally identified as an intermediate filament protein present only as an intracellular component in many cell types. However, this protein has now been detected on the surface of a number of different cancer cell types in a punctate distribution pattern. Increased vimentin expression has been indicated as an important step in epithelial-mesenchymal transition (EMT) required for the metastasis of prostate cancer. Here, using two vimentin-specific monoclonal antibodies (SC5 and V9 directed against the coil one rod domain and the C-terminus of the vimentin protein, respectively), we examined whether either of these domains would be displayed on the surface of three commonly studied prostate cancer cell lines isolated from different sites of metastases. Confocal analysis of LNCaP, PC3 and DU145 prostate cancer cell lines (derived from lymph node, bone or brain prostate metastases, respectively) demonstrated that both domains of vimentin are present on the surface of these metastatic cancer cell types. In addition, flow cytometric analysis revealed that vimentin expression was readily detected along with CD44 expression but only a small subpopulation of prostate cancer cells expressed vimentin and the putative stem cell marker CD133 along with CD44. Finally, Cowpea mosaic virus (CPMV) nanoparticles that target vimentin could bind and internalize into tested prostate cancer cell lines. These results demonstrate that at least two domains of vimentin are present on the surface of metastatic prostate cancer cells and suggest that vimentin could provide a useful target for nanoparticle- or antibody- cancer therapeutic agents directed against highly invasive cancer and/or stem cells.

References

  1. Mol Pharm. 2011 Feb 7;8(1):29-43 - PubMed
  2. N Engl J Med. 2006 Sep 21;355(12):1253-61 - PubMed
  3. Cancer Res. 2003 Sep 15;63(18):5821-8 - PubMed
  4. Nanomedicine (Lond). 2011 Feb;6(2):351-64 - PubMed
  5. Proteomics. 2007 Jun;7(12):1973-83 - PubMed
  6. Blood. 1997 Dec 15;90(12):5013-21 - PubMed
  7. J Invest Dermatol. 2001 May;116(5):731-8 - PubMed
  8. J Cell Sci. 2001 Nov;114(Pt 21):3865-72 - PubMed
  9. J Urol. 1994 Oct;152(4):1077-81 - PubMed
  10. Mol Carcinog. 2007 Jan;46(1):1-14 - PubMed
  11. Cancer Biol Ther. 2007 May;6(5):763-8 - PubMed
  12. Blood. 2006 Oct 1;108(7):2339-48 - PubMed
  13. Curr Mol Med. 2008 Dec;8(8):784-804 - PubMed
  14. EMBO J. 2002 Aug 1;21(15):3949-59 - PubMed
  15. J Immunol. 2006 Jan 1;176(1):652-9 - PubMed
  16. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6853-6 - PubMed
  17. Biochem Biophys Res Commun. 2004 Sep 3;321(4):788-94 - PubMed
  18. J Cell Biol. 2001 Nov 26;155(5):755-62 - PubMed
  19. Methods Mol Biol. 1998;81:205-9 - PubMed
  20. J Neurosurg. 1990 Dec;73(6):901-8 - PubMed
  21. Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 - PubMed
  22. J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 - PubMed
  23. Nat Rev Cancer. 2011 Apr;11(4):254-67 - PubMed
  24. PLoS Pathog. 2009 May;5(5):e1000417 - PubMed
  25. Dev Cell. 2008 Jun;14(6):818-29 - PubMed
  26. Cancer Res. 2005 Dec 1;65(23):10946-51 - PubMed
  27. Cell Death Differ. 2008 Mar;15(3):504-14 - PubMed
  28. Hum Antibodies. 2009;18(4):127-37 - PubMed
  29. Prostate. 2004 Dec 1;61(4):324-31 - PubMed
  30. Cell. 1990 Jun 29;61(7):1303-13 - PubMed
  31. Cell Stem Cell. 2007 Sep 13;1(3):313-23 - PubMed
  32. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  33. Nat Med. 2006 Mar;12(3):354-60 - PubMed
  34. Cancer. 1993 Feb 1;71(3 Suppl):1098-109 - PubMed
  35. Mol Biol Med. 1983 Sep;1(2):245-52 - PubMed
  36. Biomacromolecules. 2009 Apr 13;10(4):784-92 - PubMed
  37. Eur J Cancer Clin Oncol. 1988 May;24(5):829-38 - PubMed
  38. Nature. 2007 Jan 4;445(7123):106-10 - PubMed
  39. J Cell Biol. 2001 May 28;153(5):893-904 - PubMed
  40. J Clin Invest. 2008 Jun;118(6):2111-20 - PubMed
  41. Oncogene. 2006 Mar 16;25(12):1696-708 - PubMed
  42. Cancer Res. 2007 Jul 15;67(14):6796-805 - PubMed
  43. Br J Haematol. 2010 Sep;150(5):574-86 - PubMed
  44. Cancer Res. 2008 Mar 15;68(6):1820-5 - PubMed
  45. Zhonghua Nan Ke Xue. 2008 Sep;14(9):800-4 - PubMed
  46. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6693-4 - PubMed

Publication Types

Grant support